Tumor‑suppressive microRNA‑223 targets WDR62 directly in bladder cancer

  • Authors:
    • Satoshi Sugita
    • Hirofumi Yoshino
    • Masaya Yonemori
    • Kazutaka Miyamoto
    • Ryosuke Matsushita
    • Takashi Sakaguchi
    • Toshihiko Itesako
    • Shuichi Tatarano
    • Masayuki Nakagawa
    • Hideki Enokida
  • View Affiliations

  • Published online on: March 22, 2019     https://doi.org/10.3892/ijo.2019.4762
  • Pages: 2222-2236
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

miRNA‑223 (miR‑223) has been reported to function not only as a tumor suppressor, but also as an oncogenic microRNA (miRNA or miR) in various cancer cells. Therefore, the functional role of miR‑223 has not been elucidated to date, at least to the best of our knowledge. We previously performed the deep sequencing analysis of clinical bladder cancer (BC) specimens. It was revealed that miR‑223 expression was significantly downregulated in BC, suggesting that miR‑223 functions as a tumor suppressor miRNA in BC. The aim of this study was to investigate the functional roles of miR‑223 and to identify its targets in BC. The expression levels of miR‑223 were significantly decreased in our clinical BC specimens. The Cancer Genome Atlas (TCGA) database indicated that miR‑223 expression was related to lymphovascular invasion and distant metastasis. The restoration of miR‑223 expression significantly inhibited tumor aggressiveness and induced apoptosis via caspase‑3/7 activation in BC cells. WD repeat domain 62 (WDR62), a candidate target of miR‑223 according to in silico analyses, has been previously proposed to play a role in neurodevelopment. Direct binding between WDR62 and miR‑223 was confirmed by luciferase assay. The TCGA database revealed positive associations between WDR62 mRNA expression and a higher tumor grade and stage in BC. The knockdown of WDR62 significantly inhibited tumor aggressiveness and induced the apoptosis of BC cells. On the whole, the findings of this study reveal a novel miR‑223 target, oncogenic WDR62, and provided insight into the oncogenesis of BC.
View Figures
View References

Related Articles

Journal Cover

June 2019
Volume 54 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Sugita, S., Yoshino, H., Yonemori, M., Miyamoto, K., Matsushita, R., Sakaguchi, T. ... Enokida, H. (2019). Tumor‑suppressive microRNA‑223 targets WDR62 directly in bladder cancer. International Journal of Oncology, 54, 2222-2236. https://doi.org/10.3892/ijo.2019.4762
MLA
Sugita, S., Yoshino, H., Yonemori, M., Miyamoto, K., Matsushita, R., Sakaguchi, T., Itesako, T., Tatarano, S., Nakagawa, M., Enokida, H."Tumor‑suppressive microRNA‑223 targets WDR62 directly in bladder cancer". International Journal of Oncology 54.6 (2019): 2222-2236.
Chicago
Sugita, S., Yoshino, H., Yonemori, M., Miyamoto, K., Matsushita, R., Sakaguchi, T., Itesako, T., Tatarano, S., Nakagawa, M., Enokida, H."Tumor‑suppressive microRNA‑223 targets WDR62 directly in bladder cancer". International Journal of Oncology 54, no. 6 (2019): 2222-2236. https://doi.org/10.3892/ijo.2019.4762